| Code | CSB-RA020067MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to zilovertamab, targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is an oncofetal surface antigen that plays a critical role in embryonic development but exhibits restricted expression in healthy adult tissues. This receptor is aberrantly expressed in various hematologic malignancies and solid tumors, including chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and certain breast and lung cancers. ROR1 contributes to cancer cell survival, proliferation, and chemotherapy resistance through activation of non-canonical Wnt signaling pathways, making it an attractive therapeutic target in oncology.
Zilovertamab is a fully humanizedized IgG1 monoclonal antibody designed to bind ROR1 and mediate antibody-dependent cellular cytotoxicity against ROR1-expressing tumor cells. This biosimilar antibody serves as a valuable research tool for investigating ROR1 biology, validating ROR1 as a biomarker in various cancer types, and exploring antibody-based therapeutic strategies. It enables researchers to conduct preclinical studies examining tumor cell targeting, immune effector functions, and combination therapy approaches in oncology research.
There are currently no reviews for this product.